

Mesh Related Pudendal Neuralgia: Future Care Going to Taxpayers

Future care cost for pudendal neuralgia following complete mesh removal for those who suffer from chronic pain is an enormous financial burden.

SANTA BARBARA, CA, UNITED STATES OF AMERICA, April 11, 2019 /EINPresswire.com/ -- Devices such as the Johnson & Johnson's TVT-O and Prolift device and the Boston Scientific's Pinnacle Pelvic Floor System and Obtryx device by design unreasonably place the pudendal nerve in peril. The result of these devices left several thousand catastrophically injured women in need for lifetime medical services including physical therapy, medication management, pudendal nerve blocks, and other invasive therapies. Future care cost for pudendal neuralgia following complete mesh removal for those who suffer from chronic pain is an enormous financial burden that will, for the most part, be paid for by government payor sources for the next 3-4 decades. The result is a huge financial burden on taxpayers who fund the Medicare and Medicaid programs that serve the medically



indigent women who become disabled from the vaginal mesh debacle.

Dr. Greg Vigna, MD, JD, damages expert, Certified Life Care Planner, and pharmaceutical injury attorney recognizes this as an "unacceptable cost shift from the defendant manufacturers to the



The cost of care being passed to taxpayers is staggering. When you just think about Interstim, an FDA approved treatment for chronic pelvic pain, the trial and implant cost approximately \$96,404.00."

Dr. Greg Vigna

taxpayers. These unacceptable costs have become the basis of lawsuits by State Attorney Generals in California, Washington State, and Mississippi in an attempt to recoup the financial harm to the States."

Dr. Vigna has researched the national cost of care for essential medical and non-medical services required in the management of mesh complications including Complex Regional Pain Syndrome, Pudendal Neuralgia, and Obturator Neuralgia and the cost of necessary care for a 50-year-old woman to their expected life expectancy can be between 1.5-2.5 million dollars. Dr. Vigna states, "The cost of care being passed to taxpayers is staggering. When

you just think about Interstim, an FDA approved treatment for chronic pelvic pain, the trial and implant cost approximately \$96,404.00."

Dr. Vigna goes on, "Compounding this issue has been the unacceptable compensation for catastrophically injured women negotiated by the various settlements that largely left behind those who are most injured. With every inadequate settlement that is accepted by an injured woman who believes there are no other litigation option for adequate compensation or those who financially have no other choice to accept an inadequate matrix settlement, there is an inadequate amount funded to the required Medicare Set-Aside amount to protect government payor sources going forward. Essentially, inadequate compensation is pushing the financial

burden to taxpayers as opposed to the manufacturer's shareholders."

For more information regarding diagnoses and treatment of transvaginal mesh complications go to https://tvm.lifecare123.com/ and for video resources visit https://tvm.lifecare123.com/ page/videos.html .

Greg Vigna Greg Vigna, M.D., J.D. +1 800-761-9206 email us here Visit us on social media: Facebook Twitter

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.